Physician profile
Andre B Aung
NPI 1750802880
$7,223.16
in general payments reported to CMS, 2019-2025
22 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $741 · 2020: $209 · 2021: $110 · 2022: $2,477 · 2023: $1,453 · 2024: $1,375 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,685.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $2,338.30 | 2022-2025 | Miebo, Envista Mx60 Iol, Xiidra |
| Alcon Vision LLC | $814.80 | 2019-2023 | Argos, Hydrus Microstent, Clareon |
| Horizon Therapeutics Plc | $668.06 | 2022-2023 | Tepezza |
| Sight Sciences, INC. | $632.92 | 2023-2025 | Omni Surgical System |
| Amgen INC. | $488.99 | 2024-2025 | Tepezza, Uplizna |
| New World Medical,INC. | $423.25 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $381.03 | 2019-2023 | Eylea |
| Glaukos Corporation | $359.20 | 2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Carl Zeiss Meditec USA, INC. | $156.85 | 2024 | Veracity Surgical |
| Novartis Pharmaceuticals Corporation | $147.70 | 2019-2023 | |
| Rxsight INC | $137.12 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $127.59 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $118.74 | 2024-2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $98.14 | 2024 | Syfovre |
| Alexion Pharmaceuticals, INC. | $84.15 | 2023-2024 | Ultomiris |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81.71 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $45.11 | 2019 | |
| Astellas Pharma US INC | $32.40 | 2024 | Izervay |
| Ivantis, INC | $28.04 | 2020 | |
| Oyster Point Pharma, INC. | $22.53 | 2025 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $22.22 | 2022 | |
| Allergan, INC. | $14.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Aung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.